{ "id": "antihistamine", "title": "Antihistamine", "lang": "en", "source_lang": "en", "summary": "A drug that opposes histamine receptor activity, commonly used to relieve allergic symptoms or reduce gastric acid secretion.", "category": "health", "subcategory": "drugs", "type": "concept", "aliases": [ "Antihistamines", "anti-histamine", "histamine receptor blocker" ], "generated_at": "2026-10-15", "model": "gpt-6.1-sol", "url": "https://aiwiki.page/en/antihistamine/", "translations": { "zh-Hans": { "url": "https://aiwiki.page/zh/antihistamine/", "json": "https://aiwiki.page/zh/antihistamine.json" } }, "sections": [ { "heading": "", "text": "An antihistamine is a drug that opposes the activity of histamine at its receptors. In ordinary medical usage, the term most often refers to H1 antihistamines, which relieve symptoms of allergy, including sneezing, itching, watery eyes, and hives. A broader pharmacological usage also encompasses drugs targeting other histamine receptor subtypes, particularly H2 blockers used to reduce stomach acid secretion. Most established H1 antihistamines act as inverse agonists, stabilizing an inactive receptor state rather than simply preventing histamine from binding. (nhs.uk)\n\nAntihistamines illustrate how receptor selectivity and access to the central nervous system shape a medicine’s effects. Older H1 drugs commonly cause sedation, whereas newer agents, including cetirizine and loratadine, generally have less sedating activity. Other histamine-targeting drugs have distinct applications: H2 blockers treat acid-related disorders, while the H3 antagonist/inverse agonist pitolisant is used in narcolepsy. These differences underpin the classification, mechanisms, clinical uses, and safety considerations of the group. H1 antihistamines have only a limited adjunctive role in anaphylaxis and do not replace epinephrine. (nhs.uk)" }, { "heading": "Definition and receptor-based classification", "text": "An antihistamine is a drug that opposes the activity of histamine at its receptors. In everyday clinical and consumer usage, the term usually means an H1 antihistamine: an allergy medicine such as cetirizine or loratadine, used to relieve symptoms of allergic rhinitis, urticaria, or allergic conjunctivitis. In broader pharmacological classification, histamine antagonists include drugs directed against other histamine receptor subtypes, not only those used for allergy. “Antihistamine” therefore identifies a receptor-related action rather than a single therapeutic indication or chemical structure. (nhs.uk)\n\nThere are four recognized histamine receptor subtypes, designated H1, H2, H3, and H4. All belong to the G-protein-coupled receptor family, but they differ in molecular structure, tissue distribution, and pharmacological responses. H1 receptors mediate many familiar effects associated with immediate allergic reactions, including itching and increased vascular permeability. H2 receptors are important in stimulating gastric acid secretion, making H2 antagonists such as famotidine a distinct group from H1 allergy medicines. These associations are not exclusive anatomical assignments: a receptor subtype can occur in several tissues and participate in more than one physiological process. (doi.org)\n\nH3 receptors have a prominent neuronal role, regulating the release of histamine and other neurotransmitters; drugs directed against them consequently have a pharmacological profile different from peripheral H1 blockers. H4 receptors are associated particularly with immune-system cells and responses such as directed cell migration. Their molecular identification was reported in 2000–2001; a 2001 cloning study described H4 as a fourth G-protein-coupled histamine receptor, with 58% amino-acid identity to H3 within its transmembrane regions. Thus, the numbers distinguish receptor subtypes, not successive improvements in allergy medication. (guidetopharmacology.org)\n\nThe first- and second-generation labels apply principally to subdivisions within the H1 group. First-generation drugs, exemplified by diphenhydramine, generally enter the brain more readily and commonly cause sedation. Second-generation agents, including cetirizine and loratadine, generally show greater receptor specificity and lower penetration of the blood–brain barrier, although reduced sedation does not mean that drowsiness is impossible. Both generations target H1 receptors: “second-generation antihistamine” does not mean “H2 antagonist.” The National Library of Medicine explicitly places non-sedating, second-generation H1 antagonists beneath the broader H1-antagonist category. Many H1 medicines are more precisely described as inverse agonists, which reduce the receptor’s intrinsic activity, rather than merely preventing histamine-induced activation. (ncbi.nlm.nih.gov)\n\nReceptor blockade must also be distinguished from preventing histamine synthesis or release. An antihistamine acts at the receiving receptor; this action does not, by itself, establish inhibition of the enzymes producing histamine or prevention of its discharge from storage cells. Some compounds have additional actions, but those are separate pharmacological properties. Moreover, allergic inflammation involves mediators besides histamine, including leukotrienes, prostaglandins, and cytokines. Blocking H1 receptors therefore suppresses selected histamine-mediated responses rather than neutralizing every inflammatory mediator or eliminating the underlying allergic sensitization. (meshb.nlm.nih.gov)" }, { "heading": "Histamine signaling and mechanisms of drug action", "text": "Histamine acts both as a locally released tissue mediator and as a neurotransmitter. Mast cells and basophils store it in secretory granules and release it by degranulation in response to immune or nonimmune stimuli. In immediate allergic reactions, an allergen can cross-link receptor-bound IgE antibodies, initiating signaling that triggers granule release. Histamine also has functions independent of allergy: enterochromaffin-like cells release it within the gastric mucosa to stimulate acid secretion, while histamine-releasing neurons participate in central nervous system signaling, including the regulation of wakefulness. These sources deliver the same chemical messenger into different cellular environments. (nature.com)\n\nAll four histamine receptor subtypes are G-protein-coupled receptors: membrane proteins with seven transmembrane helices that translate extracellular ligand binding into intracellular signaling. Their principal coupling associations are H1 with \\(G_{q/11}\\), H2 with \\(G_s\\), and H3 and H4 with \\(G_{i/o}\\). H1 activation stimulates phospholipase C, generating inositol trisphosphate and diacylglycerol and increasing intracellular calcium. H2–\\(G_s\\) signaling activates adenylyl cyclase and raises cyclic AMP; \\(G_{i/o}\\)-linked signaling generally inhibits adenylyl cyclase and can regulate additional cellular effectors. These are predominant associations rather than exclusive pairings: experimental studies also demonstrate H2 coupling to \\(G_q\\). (nature.com)\n\nReceptor location determines the physiological consequences of these signals. Vascular H1 activation increases permeability, allowing fluid to move into tissues, while H1 signaling in sensory nerves contributes to histamine-evoked itching. Blocking these receptors therefore reduces particular components of swelling and sensory irritation. In gastric parietal cells, H2-dependent cyclic AMP signaling stimulates acid secretion; H2 blockade interrupts this stimulatory pathway rather than neutralizing acid already present. The dependence on H2 signaling was demonstrated experimentally in H2-receptor-deficient mice, which lacked the normal acid-secretory response to histamine. (nature.com)\n\n“Antagonism” and “inverse agonism” describe different effects on receptor activity. A neutral antagonist prevents an agonist such as histamine from activating its receptor but does not itself reduce the receptor’s basal activity. An inverse agonist preferentially stabilizes inactive receptor conformations, reducing constitutive signaling—that is, activity occurring even without an agonist. Many H1 medicines conventionally called antagonists act as inverse agonists. In 2011, Tatsuro Shimamura and colleagues determined the human H1 receptor–doxepin crystal structure at 3.1 Å resolution. Doxepin contacted Trp428, a residue associated with receptor activation, providing a structural explanation for stabilization of an inactive state. A 2021 cryo-electron microscopy study of histamine-bound H1–\\(G_q\\) showed the contrasting active configuration, with an intracellular cavity open for G-protein engagement. (pmc.ncbi.nlm.nih.gov)\n\nH3 receptors illustrate why opposing histamine signaling need not simply suppress cellular activity. On histamine-releasing neurons, presynaptic H3 autoreceptors provide inhibitory feedback; H3 receptors can also regulate release from neurons using other transmitters. Blocking this inhibitory receptor can therefore increase transmitter release. Constitutive H3 signaling has been demonstrated in recombinant human receptors and native brain preparations, making inverse agonism relevant even without added histamine. H4 receptors, by contrast, are prominent in immune-cell signaling, including directed cell migration. Consequently, receptor blockade has different functional consequences depending on both receptor subtype and the cell expressing it. (pmc.ncbi.nlm.nih.gov)" }, { "heading": "Discovery and historical development", "text": "In 1937, Daniel Bovet and Anne-Marie Staub demonstrated synthetic antihistamine activity at the Institut Pasteur in Paris, where Bovet worked in Ernest Fourneau’s therapeutic chemistry department. The discovery belonged to a broader experimental program: identifying synthetic compounds that opposed substances produced within the body. Drugs blocking the effects of epinephrine and acetylcholine provided precedents for seeking an antagonist of histamine. Rather than beginning with a molecularly identified receptor, this research compared chemical structures with their effects in biological preparations. Bovet’s earlier discovery of a synthetic adrenergic blocking agent in 1933 formed part of the same approach to pharmacology. (pasteur.fr)\n\nThe early antihistamine compound 929 F, a thymol ether associated with Bovet and Staub’s 1937 experiments, established a pharmacological effect but was too toxic for human use. Staub subsequently investigated phenylethylenediamine derivatives. A clinically usable compound emerged in 1942 as Antergan, or phenbenzamine, designated 2339 RP. Bovet’s Nobel lecture credited its development to Mosnier’s synthesis, Bernard Halpern’s pharmacological analysis, and clinical investigations by several physicians. This sequence distinguished the initial demonstration that histamine responses could be inhibited from the later development of compounds suitable for treatment. In 1944, Bovet and colleagues reported the better-tolerated Neo-Antergan, subsequently known as mepyramine or pyrilamine. (nobelprize.org)\n\nDuring the 1940s, antihistamine research expanded across European and American laboratories. Bovet’s historical account listed pyrilamine in 1944, diphenhydramine and tripelennamine in 1945, promethazine in 1946, and chlorphenamine in 1949. He estimated that approximately 500 chemists had carried out 5,000 syntheses in less than ten years. These efforts produced active compounds belonging to several distinct chemical families, rather than a single series closely resembling histamine. Although pharmacologists could identify competitive antagonism experimentally, Bovet emphasized the largely empirical character of the chemical discoveries: structural similarity alone did not readily explain why these diverse compounds shared antihistamine activity. (nobelprize.org)\n\nBovet received the Nobel Prize in Physiology or Medicine in 1957, but the award was not restricted to antihistamine discovery. Its citation recognized discoveries concerning synthetic compounds that inhibited endogenous substances, particularly their effects on blood vessels and skeletal muscles. Antihistamines therefore represented one branch of a wider body of work that also included adrenergic blocking agents and synthetic curare-like muscle relaxants. Gallamine, introduced clinically by Bovet, Depierre, and Courvoisier in 1946, exemplified the neuromuscular component of that research. (nobelprize.org)\n\nReceptor-based differentiation subsequently supplied a more explicit framework for selective drug development. In 1972, James Black, William Duncan, John Durant, Robin Ganellin, and Michael Parsons reported the definition and antagonism of histamine H2 receptors using burimamide. Its activity distinguished H2-mediated responses from those blocked by conventional H1 antihistamines. In Black’s account, burimamide remained a prototype because of limited potency and poor oral bioavailability; chemical modification produced metiamide and then cimetidine. This program used a proposed receptor distinction, quantitative tissue assays, and successive structural modifications to develop selective antagonists, extending antihistamine research beyond the early allergy medicines. (pubmed.ncbi.nlm.nih.gov)" }, { "heading": "H1 antihistamines: generations and chemical families", "text": "H1 antihistamines are commonly divided into first- and second-generation drugs according to their functional pharmacology, particularly their effects on the central nervous system. Diphenhydramine, chlorphenamine—called chlorpheniramine in the United States—hydroxyzine, and promethazine are first-generation examples; cetirizine, loratadine, and fexofenadine belong to the second generation. The older agents generally enter the brain more readily and can produce sedation and psychomotor impairment. Second-generation agents have more restricted brain exposure and are consequently described as less-sedating or relatively nonsedating. These labels describe a pharmacological distinction, not an absolute separation between drugs that can and cannot cause drowsiness. (nhtsa.gov)\n\nTwo properties underlie this distinction: access to central H1 receptors across the blood–brain barrier, and selectivity for H1 receptors rather than other receptor types. Peripheral selectivity means that a drug acts predominantly outside the brain; it does not imply a separate peripheral H1 receptor subtype. First-generation compounds can also interact with non-histamine receptors, although their profiles differ substantially. In a 1987 receptor-binding study, N. Kubo and colleagues found high muscarinic-receptor affinity for promethazine but much lower affinity for hydroxyzine, demonstrating that membership in the first generation does not imply identical antimuscarinic activity. Second-generation drugs generally have greater H1 selectivity and fewer such off-target effects. (nhtsa.gov)\n\nDifferences also exist within the second generation. In a 2004 double-blind, placebo-controlled crossover study, Manabu Tashiro and colleagues compared fexofenadine, cetirizine, and the first-generation comparator hydroxyzine in 20 healthy volunteers. Positron-emission tomography in 12 participants found negligible brain H1-receptor occupancy after fexofenadine 120 mg, compared with 26% after cetirizine 20 mg. Fexofenadine did not differ significantly from placebo on the psychomotor tests, whereas cetirizine produced greater impairment on some tasks. These results concern the specific doses and conditions studied, but illustrate why a shared generation label does not establish identical central effects. (pubmed.ncbi.nlm.nih.gov)\n\nChemical classification is a separate system, traditionally distinguishing six major families. Ethanolamines include diphenhydramine and clemastine; ethylenediamines include pyrilamine and tripelennamine; alkylamines include chlorphenamine and brompheniramine; piperazines include hydroxyzine and cetirizine; piperidines include loratadine and fexofenadine; and phenothiazines include promethazine. These names describe molecular structural relationships rather than degrees of sedation. Accordingly, a chemical family can span generations: hydroxyzine is a first-generation piperazine, whereas cetirizine is a second-generation piperazine. Chemical family therefore cannot substitute for the functional classification when describing brain penetration or receptor selectivity. (nhtsa.gov)\n\nRelationships between individual compounds further cut across these categories. Desloratadine is a major active product of loratadine metabolism, whereas levocetirizine represents a stereochemical relationship: it is the \\(R\\)-enantiomer of racemic cetirizine, rather than a metabolite of it. Its prescribing information reports approximately twice cetirizine’s affinity for the human H1 receptor in vitro, while explicitly stating that the clinical relevance of that difference is unknown. (dailymed.nlm.nih.gov) Such derivatives are sometimes described as “third-generation” antihistamines, but this is not a universally standardized category equivalent to the first-/second-generation distinction. In 2003, the Consensus Group on New-Generation Antihistamines, chaired by Stephen T. Holgate, proposed evaluating new-generation claims through demonstrated clinical advantages, central effects, cardiac safety, and interaction potential, rather than molecular derivation alone. (onlinelibrary.wiley.com)" }, { "heading": "Distribution, metabolism, and pharmaceutical formulations", "text": "Entry into the central nervous system depends on drug distribution, not simply on affinity for the H1 receptor. The blood–brain barrier restricts passive entry of polar or ionized molecules, while efflux transporters such as P-glycoprotein can return drugs toward the blood. Experimental studies of fexofenadine demonstrate contributions from both low passive permeability and transporter-mediated efflux. These properties are distinct from receptor binding: experiments with cetirizine found similar potency at brain and lung H1 receptors, despite restricted entry into the brain. Thus, peripheral selectivity can reflect limited access to central receptors rather than an inability to bind them. (pubmed.ncbi.nlm.nih.gov)\n\nPharmacokinetics describes absorption, distribution, metabolism, and elimination. Bioavailability concerns the rate and extent of availability after administration; for systemic exposure, its extent is expressed as the fraction reaching the circulation. Clearance is the volume of plasma effectively cleared of drug per unit time, whereas elimination half-life is the time required for plasma concentration to fall by half during the elimination phase. Neither the time of peak plasma concentration nor elimination half-life directly specifies clinical onset or duration. For cetirizine, labeling reports peak concentrations at approximately one hour and a mean half-life of 8.3 hours, while suppression of experimentally induced histamine skin responses can persist for at least 24 hours. Generation labels therefore cannot substitute for drug-specific measurements of absorption and effect. (fda.gov)\n\nMetabolic pathways differ substantially among H1 antihistamines. Loratadine undergoes extensive first-pass hepatic metabolism, principally through the enzymes CYP3A4 and CYP2D6, producing the active metabolite desloratadine. Its product information gives mean elimination half-lives in healthy adults of 8.4 hours for loratadine and 28 hours for desloratadine; both compounds contribute to antihistaminic activity. Cetirizine, by contrast, undergoes limited metabolism. In a radiolabeled mass-balance study involving six healthy men, approximately 70% of administered radioactivity was recovered in urine and 10% in feces; unchanged cetirizine accounted for approximately 50% of the administered dose in urine. Renal elimination is consequently an important determinant of its exposure, and reduced kidney function can prolong elimination. (medicines.org.uk)\n\nAbsorption also depends on intestinal transport and formulation conditions. In a 2002 randomized crossover study of ten healthy volunteers, grapefruit, orange, or apple juice reduced fexofenadine exposure, measured by the area under the plasma concentration–time curve, to approximately 30–40% of that observed with water under the study conditions. Elimination half-life and renal clearance were unchanged. Accompanying cell experiments demonstrated inhibition of organic anion transporting polypeptide-mediated uptake, supporting reduced intestinal absorption rather than accelerated elimination as the explanation. This illustrates why exposure can change independently of receptor affinity or elimination half-life. (pubmed.ncbi.nlm.nih.gov)\n\nFormulations include oral tablets, capsules, solutions and syrups; nasal sprays; ophthalmic drops; and cutaneous creams, lotions and gels. Oral products provide systemic delivery, whereas nasal, ocular and cutaneous preparations place drug at a local treatment site. Local administration does not necessarily exclude systemic exposure: azelastine nasal spray has approximately 40% systemic bioavailability, while studies of olopatadine ophthalmic solution generally found plasma concentrations below 0.5 ng/mL. Injectable formulations provide another systemic route: diphenhydramine injection is formulated for intravenous or deep intramuscular administration, and cetirizine is available as an intravenous product. These routes and formulations are separate pharmaceutical characteristics from an antihistamine’s receptor target or generation. (nhs.uk)" }, { "heading": "Clinical uses and limits of H1 antihistamines", "text": "In allergic rhinitis, H1 antihistamines reduce sneezing, nasal itching, and watery nasal discharge by opposing histamine’s effects on sensory nerves and other target tissues. Oral agents such as cetirizine and loratadine can also relieve accompanying ocular symptoms. Their effect on nasal obstruction is generally less pronounced than their effect on itching and sneezing; intranasal antihistamines can improve congestion as well as other nasal symptoms. In allergic conjunctivitis, antihistamine eye drops provide local relief of itching, redness, and watering. These indications concern allergic inflammation rather than every cause of a runny nose or red eye: infectious conjunctivitis and non-allergic rhinitis do not necessarily respond in the same way. (pmc.ncbi.nlm.nih.gov)\n\nIn urticaria, H1 blockade suppresses itching and the formation of raised wheals associated with histamine release in the skin. Less-sedating oral antihistamines are established symptomatic treatments for both acute and chronic disease. Their usefulness does not establish that an episode has an external allergic cause: acute urticaria can accompany infections, while chronic spontaneous urticaria often has no identifiable external trigger. Antihistamines also relieve itching and some swelling in selected localized reactions, including insect bites and stings. However, symptom relief is distinct from elimination of the provoking process, and persistent or recurrent urticaria may remain incompletely controlled despite H1 blockade. (rch.org.au)\n\nThese effects represent suppression of histamine-mediated symptoms, not removal of allergic sensitization. Blocking a receptor does not eliminate allergen-specific antibodies or establish lasting immune tolerance to an allergen. Consequently, improvement during treatment does not demonstrate that the underlying allergy has disappeared. Histamine is also only one component of allergic inflammation, which helps explain why antihistamines may control itching and sneezing without adequately controlling every manifestation of disease. This distinguishes their symptomatic action from allergen immunotherapy, which is intended to alter the response to a specific allergen. (pmc.ncbi.nlm.nih.gov)\n\nSelected centrally acting H1 antihistamines have separate, non-allergic uses. Dimenhydrinate, meclizine, and promethazine are used against motion sickness and its associated nausea and vomiting. Their effectiveness depends on action within the central nervous system, including pathways processing vestibular signals; the CDC’s 2026 Yellow Book distinguishes them from minimally sedating agents such as cetirizine and loratadine, which are ineffective for motion sickness because of their limited brain penetration. Diphenhydramine is also used for short-term insomnia, exploiting central sedation rather than an antiallergic effect. Such use is distinct from treatment of chronic sleep disorders, and its sleep-promoting effect can diminish with prolonged use. (cdc.gov)\n\nIn anaphylaxis, H1 antihistamines have a much narrower role: they may relieve itching and hives but do not reliably reverse life-threatening airway, respiratory, or circulatory compromise. Intramuscular epinephrine remains the first-line treatment, rather than an antihistamine. The World Allergy Organization’s 2020 guidance notes that some guidelines place antihistamines third-line because their administration can delay more urgent interventions, including additional epinephrine. Reduction of a rash therefore cannot be taken as evidence that the systemic reaction has resolved. Sedation can also complicate assessment, and rapid intravenous administration of certain first-generation agents can itself produce hypotension. (pmc.ncbi.nlm.nih.gov)" }, { "heading": "H2 antihistamines and acid-related disorders", "text": "H2 antihistamines suppress gastric acid secretion by blocking histamine H2 receptors on the acid-secreting parietal cells of the stomach. Histamine normally stimulates these receptors, increasing intracellular cyclic AMP and activating processes that promote hydrochloric acid secretion. H2 blockade interrupts this stimulatory pathway rather than removing histamine or chemically consuming acid. Cimetidine and famotidine are representative competitive H2-receptor inhibitors. Their receptor target distinguishes them from H1 antihistamines used for allergic symptoms: the designation “H2” identifies a different histamine receptor subtype, not a later generation of H1 allergy medicines. (pubmed.ncbi.nlm.nih.gov)\n\nThe antisecretory effect extends beyond acid production elicited experimentally by histamine alone. Cimetidine inhibits basal daytime and nocturnal secretion, together with secretion stimulated by food and pentagastrin, a synthetic gastrin analogue. Famotidine likewise suppresses basal, nocturnal, and food-stimulated secretion, reducing both gastric juice volume and acid concentration. Its prescribing information reports an onset of antisecretory activity within one hour after oral administration and a maximum effect within one to three hours. These measurements describe inhibition of secretion, rather than the time required for an ulcer or damaged esophageal lining to heal. (dailymed.nlm.nih.gov)\n\nThe U.S. famotidine tablet labeling revised in September 2025 includes active gastric and duodenal peptic ulcers, symptomatic nonerosive gastroesophageal reflux disease, and erosive esophagitis due to reflux. Adult indications also include pathological hypersecretory conditions, such as Zollinger–Ellison syndrome, and reduction of duodenal ulcer recurrence. Clinical evidence encompasses tissue healing as well as symptom relief: in a U.S. multicenter, double-blind duodenal-ulcer trial described in the labeling, endoscopically confirmed healing at four weeks occurred in 70% of patients receiving the studied 40-mg bedtime famotidine regimen, compared with 31% receiving placebo. These figures concern that trial and regimen, rather than a uniform response across acid-related disorders. (dailymed.nlm.nih.gov)\n\nH2 blockers differ mechanistically from both antacids and proton-pump inhibitors. Antacids neutralize acid already present in the gastric contents; they do not principally act through histamine receptors. By contrast, omeprazole inhibits the parietal-cell \\(\\mathrm{H^+/K^+}\\)-ATPase, the enzyme system responsible for the final step of gastric acid secretion. Its action therefore suppresses basal and stimulated secretion irrespective of the initiating stimulus. Famotidine acts upstream at a histamine receptor, whereas omeprazole acts at the acid pump itself; a shared acid-lowering purpose does not place them in the same drug class. In reflux disease, proton-pump inhibitors generally provide greater healing of the esophageal lining than H2 blockers. (niddk.nih.gov)" }, { "heading": "H3-targeted medicines and H4 research", "text": "H3 receptors regulate neuronal signaling rather than simply mediating peripheral allergic symptoms. On histamine-releasing neurons, they function as autoreceptors: histamine activates a negative-feedback mechanism that restrains its own synthesis and release. On neurons releasing other neurotransmitters, they function as heteroreceptors, modulating the release of substances including noradrenaline, dopamine, and serotonin. Experimental work has demonstrated these effects in mammalian brain preparations, including human tissue. H3 receptors couple to inhibitory \\(G_{i/o}\\) proteins; their activation can inhibit adenylyl cyclase and voltage-activated calcium channels. Consequently, blocking H3-mediated feedback can enhance transmitter release, unlike peripheral H1 blockade, which suppresses histamine-mediated allergic responses. (pubmed.ncbi.nlm.nih.gov)\n\nPitolisant, marketed as Wakix, is an H3 antagonist/inverse agonist used in narcolepsy. Antagonism opposes histamine-induced receptor activation, whereas inverse agonism also reduces receptor activity occurring without bound histamine. Its receptor selectivity is pronounced: the United States prescribing information reports an H3 binding affinity of \\(K_i = 1\\ \\mathrm{nM}\\), with no appreciable binding to H1, H2, or H4 receptors at much higher concentrations. The February 2026 labeling specifies treatment of excessive daytime sleepiness or cataplexy in patients aged six years and older with narcolepsy. Nevertheless, the label explicitly distinguishes this established receptor activity from the incompletely understood therapeutic mechanism: clinical efficacy could be mediated through H3 antagonism/inverse agonism, but the complete mechanism producing benefit remains unclear. (pmc.ncbi.nlm.nih.gov)\n\nHuman positron-emission tomography (PET) provides direct evidence that pitolisant reaches and occupies brain H3 receptors. A study published in 2020 examined six healthy adults using the H3-binding radioligand \\([^{11}\\mathrm{C}]\\mathrm{GSK189254}\\). Each participant underwent scans on separate days after placebo and after a single oral administration of 40 mg pitolisant hydrochloride. Scanning three hours after administration showed mean receptor occupancy of \\(84\\% \\pm 7\\%\\), expressed as mean ± standard deviation. Reduced radioligand binding demonstrated central target engagement. Because this was a small study in healthy volunteers, the occupancy measurement did not itself establish improvement in sleepiness or cataplexy, nor demonstrate efficacy for other neurological disorders. (pmc.ncbi.nlm.nih.gov)\n\nH4-directed research instead focuses on histamine’s influence on the immune system and inflammation. Experiments with isolated human eosinophils demonstrated H4-dependent changes in cell shape, increased expression of adhesion molecules, and migration along a histamine concentration gradient. A 2004 study distinguished this directed migration, or chemotaxis, from a nonspecific increase in movement: disrupting the concentration gradient abolished migration. These findings provided a mechanistic rationale for investigating whether H4 antagonists could reduce inflammatory-cell recruitment, rather than merely suppress the immediate symptoms addressed by H1 medicines. They constitute cellular evidence, not proof of therapeutic benefit in patients. (pmc.ncbi.nlm.nih.gov)\n\nClinical investigation has included the selective H4 antagonist ZPL-3893787 in atopic dermatitis. In an eight-week, double-blind randomized controlled trial, 65 adults received the investigational compound and 33 received placebo. Eczema Area and Severity Index scores decreased by 50% with ZPL-3893787 versus 27% with placebo. However, improvement in the separately assessed pruritus score did not differ significantly between groups (\\(P = .249\\)). The divergence between skin-lesion and itching outcomes illustrates why H4 receptor biology cannot establish a general clinical indication: this trial supplied evidence about particular outcomes for an experimental compound, not an established indication for H4 antagonists as a class. (pubmed.ncbi.nlm.nih.gov)" }, { "heading": "Adverse effects, interactions, and population differences", "text": "Sedating H1 antihistamines, including diphenhydramine, chlorphenamine, and promethazine, can impair coordination, reaction speed, and judgment as well as cause sleepiness. These effects reflect activity in the central nervous system and can interfere with driving or operating machinery. “Less-sedating” does not mean incapable of causing sedation: cetirizine, for example, carries labeling warnings about somnolence and impaired alertness. Individual drugs also differ in their antimuscarinic activity. Diphenhydramine’s atropine-like effects include dry mouth, blurred vision, constipation, and urinary retention; its labeling identifies narrow-angle glaucoma, symptomatic prostatic enlargement, and bladder-neck obstruction as conditions requiring particular caution. (nhs.uk)\n\nInteractions can amplify impairment or increase drug exposure through separate mechanisms. Alcohol and other central nervous system depressants, including hypnotics and tranquilizers, have additive effects with diphenhydramine; monoamine oxidase inhibitors can prolong and intensify its anticholinergic effects. Cetirizine labeling likewise warns of additional reductions in alertness with alcohol or other depressants. Combination cough-and-cold remedies may already contain an antihistamine, creating inadvertent duplication when taken alongside a separate allergy medicine. Interactions are not confined to H1 drugs: the H2 blocker cimetidine inhibits hepatic metabolism of medicines including warfarin, phenytoin, and theophylline, delaying elimination and increasing their blood concentrations. Its labeling documents clinically significant interactions with these agents. (dailymed.nlm.nih.gov)\n\nCardiac electrophysiological risk is drug-specific rather than an identical property of all antihistamines. Hydroxyzine can block hERG potassium channels, interfering with cardiac repolarization and producing QT prolongation, sometimes associated with the ventricular arrhythmia torsade de pointes. In 2015, the European Medicines Agency introduced restrictions following confirmation of this risk. Its product-information amendments contraindicate hydroxyzine in patients with known QT prolongation or specified risk factors, including significant hypokalaemia or hypomagnesaemia, marked bradycardia, or concurrent use of medicines known to prolong QT or induce torsade de pointes. These restrictions concern hydroxyzine specifically and cannot be transferred unchanged to every H1 antihistamine. (ema.europa.eu)\n\nAge changes both susceptibility and the applicability of safety evidence. Diphenhydramine labeling notes increased dizziness, sedation, and hypotension in older adults, while young children may show excitation rather than sedation. Hydroxyzine is not recommended for older people in the European product information because elimination is reduced and adverse reactions, including anticholinergic effects, are more likely. Pediatric restrictions also vary by molecule: United States promethazine tablet labeling contraindicates use below two years of age because respiratory depression, including fatal cases, has occurred. This is a documented contraindication, not simply an absence of pediatric studies. (dailymed.nlm.nih.gov)\n\nReduced renal function or hepatic function can prolong exposure, although the extent depends on the drug. Cetirizine labeling reports that moderate renal impairment produced approximately a threefold increase in elimination half-life and a 70% reduction in clearance compared with healthy volunteers. In a separate study of 16 patients with chronic liver disease, half-life increased by 50% and clearance decreased by 40% compared with 16 healthy subjects. Such findings distinguish altered drug elimination from increased receptor sensitivity and explain why organ function matters independently of an antihistamine’s generation. (dailymed.nlm.nih.gov)\n\nEvidence in pregnancy and breastfeeding must likewise be interpreted drug by drug. The UK Teratology Information Service’s March 2026 assessment found that published loratadine data did not suggest increased risks of miscarriage, congenital malformation, stillbirth, or preterm delivery, while noting methodological limitations and an absence of infant neurodevelopmental data. Reassuring findings for these measured outcomes therefore do not establish the absence of every possible effect. During breastfeeding, exposure also depends on transfer into milk: LactMed describes loratadine as having low milk levels and does not expect adverse effects in breastfed infants. These findings are distinct from safety assessments for more sedating antihistamines. (uktis.org)" }, { "heading": "Evidence assessment and pharmacovigilance", "text": "Receptor studies, pharmacokinetic investigations, clinical trials, and postmarketing surveillance answer different questions. Receptor experiments characterize binding and functional activity; pharmacokinetic studies measure drug exposure over time, including absorption, elimination, and half-life. Neither alone establishes the magnitude of clinical benefit. Target engagement can be demonstrated directly: in a 2020 study, Pablo Rusjan and colleagues used positron-emission tomography in six healthy adults and measured mean brain H3-receptor occupancy of \\(84 \\pm 7\\%\\) three hours after pitolisant hydrochloride administration. This showed that the drug reached and occupied its intended receptor under the study conditions; the experiment did not itself establish improvement in narcolepsy symptoms or long-term outcomes. (pmc.ncbi.nlm.nih.gov)\n\nFor allergy medicines, clinically relevant comparisons concern the degree of symptom relief, its onset and persistence across the dosing interval, and effects on everyday functioning. Reduced sneezing or itching is a different outcome from preserved alertness, coordination, or work performance. The NHS notes that evidence does not establish any particular antihistamine as universally better than the others for relieving allergy symptoms, and individual responses vary. Consequently, superiority on one endpoint—such as reduced drowsiness—does not establish superiority for every indication or patient population. Comparisons must distinguish symptom control from adverse effects that can themselves impair quality of life. (nhs.uk)\n\nFunctional impairment can be tested rather than inferred from reported sleepiness. In a 2000 randomized controlled trial, John M. Weiler and colleagues studied 40 licensed drivers with seasonal allergic rhinitis using a double-blind, four-period crossover design. Participants received fexofenadine, diphenhydramine, alcohol, or placebo before simulated driving. Performance after fexofenadine was similar to placebo, whereas diphenhydramine impaired driving performance. Self-reported drowsiness was not a reliable predictor of impairment. These results establish differences under the tested single-dose conditions, rather than a general ranking of all antihistamines or their effectiveness against allergy symptoms. (pubmed.ncbi.nlm.nih.gov)\n\nPostmarketing pharmacovigilance can identify reactions associated with prolonged exposure or discontinuation. On May 16, 2025, the US Food and Drug Administration announced a warning about rare but severe itching after stopping long-term oral cetirizine or levocetirizine. Its review identified 209 reported cases worldwide, including 197 in the United States, submitted between April 25, 2017, and July 6, 2023. Median onset was two days after discontinuation. Patients had not experienced itching before starting the medicines. FDA concluded that its evaluation supported a causal relationship, although the underlying mechanism remained unknown; it announced prescription-label warnings and plans to request corresponding over-the-counter warnings. (fda.gov)\n\nSpontaneous reports are safety signals, not measurements of incidence. Reports may be incomplete or duplicated, reporting is selective, and an event occurring after exposure does not by itself establish causation. (fda.gov) FDA also cited an estimated 62.7 million over-the-counter packages of cetirizine and levocetirizine purchased in US retail outlets in 2022. That exposure estimate cannot serve as the denominator for the 209 cases: packages are not unique users or discontinuation episodes, and the geographic coverage and observation periods differ. Recurrence after repeated discontinuation—reported in 92 of 93 cases with that information—strengthened the causal assessment without establishing an individual’s probability of developing the reaction. (fda.gov)" } ], "links": [ "allergy", "urticaria", "central-nervous-system", "cetirizine", "loratadine", "anaphylaxis", "epinephrine", "allergic-rhinitis", "conjunctivitis", "pharmacology", "neurotransmitter", "immune-system", "brain", "inflammation", "antigen", "antibody", "stomach", "neuron", "nobel-prize-in-physiology-or-medicine", "placebo", "metabolism", "stereochemistry", "enantiomer", "pharmacokinetics", "half-life", "enzyme", "kidney", "nausea", "insomnia", "peptic-ulcer", "gastroesophageal-reflux-disease", "omeprazole", "randomized-controlled-trial", "glaucoma", "benign-prostatic-hyperplasia", "pregnancy", "clinical-trial", "quality-of-life", "incidence", "causation" ], "sources": [ { "title": "Antihistamines - NHS", "url": "https://www.nhs.uk/medicines/antihistamines/" }, { "title": "Histamine Antagonists MeSH Descriptor Data 2026", "url": "https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D006633" }, { "title": "Histamine H1 Antagonists MeSH Descriptor Data 2026", "url": "https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D006634" }, { "title": "Receptors, Histamine H2", "url": "https://meshb-prev.nlm.nih.gov/record/ui?ui=D011970" }, { "title": "Famotidine MeSH Descriptor Data 2026", "url": "https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D015738" }, { "title": "H3 receptor — IUPHAR/BPS Guide to PHARMACOLOGY", "url": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264" }, { "title": "Discovery of a novel member of the histamine receptor family", "url": "https://pubmed.ncbi.nlm.nih.gov/11179435/" }, { "title": "International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4485016/" }, { "title": "Histamine H1 Antagonists, Non-Sedating - MeSH - NCBI", "url": "https://www.ncbi.nlm.nih.gov/mesh/68039563" }, { "title": "Structural basis of ligand recognition and activation of the histamine receptor family", "url": "https://www.nature.com/articles/s41467-024-52585-y" }, { "title": "Molecular mechanism of IgE-mediated FcεRI activation", "url": "https://www.nature.com/articles/s41586-024-08229-8" }, { "title": "Abnormal functional and morphological regulation of the gastric mucosa in histamine H2 receptor–deficient mice", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC378512/" }, { "title": "Histamine H1, H3 and H4 receptors are involved in pruritus.", "url": "https://pubmed.ncbi.nlm.nih.gov/21689731/" }, { "title": "Structure of the human histamine H1 receptor complex with doxepin", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3131495/" }, { "title": "Cryo-EM structure of the human histamine H1 receptor/Gq complex", "url": "https://www.nature.com/articles/s41467-021-22427-2" }, { "title": "Histamine H3-receptor-mediated [35S]GTPγ[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1573152/" }, { "title": "Daniel Bovet (1907–1992)", "url": "https://www.pasteur.fr/en/about-us/daniel-bovet-1907-1992" }, { "title": "Daniel Bovet – Nobel Lecture", "url": "https://www.nobelprize.org/uploads/2018/06/bovet-lecture.pdf" }, { "title": "Daniel Bovet – Facts", "url": "https://www.nobelprize.org/laureate/363" }, { "title": "Definition and antagonism of histamine H2-receptors", "url": "https://pubmed.ncbi.nlm.nih.gov/4401751/" }, { "title": "James Black – Nobel Lecture", "url": "https://www.nobelprize.org/uploads/2018/06/black-lecture.pdf" }, { "title": "Antihistamines and Driving-Related Behavior: A Review of the Evidence for Impairment", "url": "https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/antihistamines20text.pdf" }, { "title": "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay", "url": "https://pubmed.ncbi.nlm.nih.gov/2884340/" }, { "title": "Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography", "url": "https://pubmed.ncbi.nlm.nih.gov/15286093/" }, { "title": "DailyMed — DESLORATADINE tablet", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36307c2b-6b6a-46a9-9fe4-1798fc72e7b8" }, { "title": "DailyMed — LEVOCETIRIZINE DIHYDROCHLORIDE tablet", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7108ad0a-af1e-4172-b4ba-e5d9aaadfba7" }, { "title": "Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration", "url": "https://pubmed.ncbi.nlm.nih.gov/19114463/" }, { "title": "Cetirizine: actions on neurotransmitter receptors", "url": "https://pubmed.ncbi.nlm.nih.gov/1979798/" }, { "title": "Guidance Recap Podcast: Bioavailability Studies Submitted in NDAs or INDs – General Considerations", "url": "https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-bioavailability-studies-submitted-ndas-or-inds-general-considerations" }, { "title": "Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry", "url": "https://www.fda.gov/media/74346/download?attachment=" }, { "title": "DailyMed — Cetirizine Hydrochloride Solution", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbea1782-20c3-45ea-bf01-4edf86d12752" }, { "title": "Loratadine 10 mg Tablets — Summary of Product Characteristics", "url": "https://www.medicines.org.uk/emc/product/8911/smpc" }, { "title": "QUZYTTIR prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211415s008lbl.pdf" }, { "title": "Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine", "url": "https://pubmed.ncbi.nlm.nih.gov/11823753/" }, { "title": "DailyMed — Astelin Azelastine Hydrochloride Spray, Metered", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944349ca-7cdb-441a-8fd0-b8616857d338" }, { "title": "DailyMed — Olopatadine Hydrochloride Solution/Drops", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7de7f9ea-53e3-4f03-b60d-31a2817b5f49" }, { "title": "DailyMed — Diphenhydramine Hydrochloride Injection", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=483fbd4c-25c7-4553-8c3f-089daca84ae6" }, { "title": "International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7286723/" }, { "title": "Clinical Practice Guidelines: Urticaria", "url": "https://www.rch.org.au/clinicalguide/guideline_index/Urticaria/" }, { "title": "Checklist: Acute Urticaria and Chronic Urticaria - ASCIA", "url": "https://www.allergy.org.au/hp/skin/acute-chronic-urticaria?highlight=WyJjaHJvbmljIiwidXJ0aWNhcmlhIl0%3D" }, { "title": "Common Myths about Allergy and Asthma", "url": "https://www.allergy.org.au/images/pc/ASCIA_PC_Common_Allergy_Myths_2024.pdf" }, { "title": "Motion Sickness — CDC Yellow Book", "url": "https://www.cdc.gov/yellow-book/hcp/travel-air-sea/motion-sickness.html" }, { "title": "About diphenhydramine - NHS", "url": "https://www.nhs.uk/medicines/diphenhydramine/about-diphenhydramine/" }, { "title": "World allergy organization anaphylaxis guidance 2020", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7607509/" }, { "title": "Gastric H+ secretion: histamine (cAMP-mediated) activation of protein phosphorylation", "url": "https://pubmed.ncbi.nlm.nih.gov/2846075/" }, { "title": "DailyMed - CIMETIDINE tablet, film coated", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01997826-7ca1-473e-bfc9-075b14b58a35" }, { "title": "The pharmacology of cimetidine, a new histamine H2-receptor antagonist", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2947417/" }, { "title": "DailyMed - CIMETIDINE tablet, film coated", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebd53065-c080-4045-a398-64d3f3b1460f" }, { "title": "DailyMed - FAMOTIDINE tablet, film coated", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e59a2c97-19c7-485c-bb1b-272ddb9ae053" }, { "title": "DailyMed - OMEPRAZOLE capsule, delayed release", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5dcf0b2-4fa2-023a-e053-2995a90a183a&version=7" }, { "title": "Treatment for GER & GERD - NIDDK", "url": "https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults/treatment" }, { "title": "Modulation of neurotransmitter release via histamine H3 heteroreceptors", "url": "https://pubmed.ncbi.nlm.nih.gov/8020871/" }, { "title": "The histamine autoreceptor is a short isoform of the H3 receptor", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3402810/" }, { "title": "H3 autoreceptors and muscarinic acetylcholine receptors modulate histamine release in the anterior hypothalamus of freely moving rats.", "url": "https://pubmed.ncbi.nlm.nih.gov/7526662/" }, { "title": "WAKIX", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211150s006lbl.pdf" }, { "title": "DailyMed - WAKIX- pitolisant hydrochloride tablet, film coated", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8daa5562-824e-476c-9652-26ceef3d4b0e" }, { "title": "Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7348085/" }, { "title": "Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1574921/" }, { "title": "Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis", "url": "https://pubmed.ncbi.nlm.nih.gov/30414855/" }, { "title": "DailyMed - CETIRIZINE HYDROCHLORIDE solution", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aeb73ab9-3b05-4062-a7fd-352cf2094a56" }, { "title": "Diphenhydramine Hydrochloride Oral Solution USP", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bf7ab250-38b0-ba29-e053-2a95a90a8f32" }, { "title": "DailyMed - CIMETIDINE tablet, film coated", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf1626a1-ccf6-4759-b2ab-22c7f3873d84" }, { "title": "Hydroxyzine: PRAC assessment report", "url": "https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-prac-assessment-report_en.pdf" }, { "title": "Hydroxyzine: Summary of Product Characteristics amendments", "url": "https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-annex-iii_en.pdf" }, { "title": "Promethazine Hydrochloride Tablets USP", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8749824b-6d66-430d-e053-2995a90a2db8&type=display" }, { "title": "DailyMed - QUZYTTIR- cetirizine hydrochloride injection", "url": "https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=573770f6-b76e-f6ba-e063-6294a90aa54d" }, { "title": "USE OF LORATADINE IN PREGNANCY – UKTIS", "url": "https://uktis.org/monographs/use-of-loratadine-in-pregnancy/" }, { "title": "Loratadine - Drugs and Lactation Database (LactMed®)", "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK501009/" }, { "title": "Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator", "url": "https://pubmed.ncbi.nlm.nih.gov/10691585/" }, { "title": "FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)", "url": "https://www.fda.gov/drugs/drug-safety-communications/fda-requires-warning-about-rare-severe-itching-after-stopping-long-term-use-oral-allergy-medicines" }, { "title": "FDA Adverse Event Monitoring System (AEMS) Public Dashboard", "url": "https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard" } ], "license": "https://creativecommons.org/licenses/by/4.0/" }